Loading...
•
Jun 30, 2021
Pulmonx Q2 2021 Earnings Report
Achieved record revenue and gross margin as procedure volumes began to normalize across key markets.
Key Takeaways
Pulmonx Corporation reported a significant increase in revenue for the second quarter of 2021, with worldwide revenue reaching $12.2 million, a 232% increase compared to the same period last year. The company's gross margin also improved significantly, reaching 74% compared to 28% in the second quarter of 2020. They are updating its full year 2021 revenue guidance to be in the range of $49 to $51 million.
Worldwide revenue increased by 232% to $12.2 million in the second quarter of 2021 compared to the same period last year.
Gross margin reached 74% in the second quarter of 2021, a significant increase from 28% in the same period last year.
20 new U.S. Zephyr® Valve treating centers were added, bringing the total to 180.
A software upgrade for Chartis® was launched to enable simpler and faster patient assessment of collateral ventilation.
Forward Guidance
Pulmonx is updating its full year 2021 revenue guidance to be in the range of $49 to $51 million. Pulmonx continues to expect total operating expenses for the full year 2021 to remain in the range of $85 to $90 million inclusive of stock-based compensation.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...